Pure Global
NCT06094010

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza

A Phase IIIb Multicenter, Single-Arm, Open-Label Surveillance Study of Susceptibility to Baloxavir Marboxil in Patients With Influenza
Hoffmann-La Roche·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Influenza
Drug/Device/Intervention
Baloxavir Marboxil
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hoffmann-La Roche
Location
Lafayette,Las Vegas, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Nov 30, 2023
End date
Jun 30, 2027
Enrollment
600 participants
Primary outcome

Percentage of Participants with Resistance-Associated Pre-Treatment Substitutions,Percentage of Participants with Resistance-Associated Treatment-Emergent Substitutions

Summary

The purpose of this study is to evaluate the pre-treatment and single-dose post treatment
 susceptibility of baloxavir marboxil in participants aged 1 to 12 years with influenza.

ICD-10 classifications
Influenza and pneumoniaInfluenza due to identified seasonal influenza virusInfluenza with other manifestations, seasonal influenza virus identifiedInfluenza with pneumonia, seasonal influenza virus identifiedInfluenza due to identified zoonotic or pandemic influenza virus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06094010
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06094010 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Influenza. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.